Asunto(s)
Cateterismo Cardíaco , Angiografía Coronaria , Procedimientos Endovasculares , Cardiopatías Congénitas/terapia , Intervención Coronaria Percutánea , Enfermedades Vasculares Periféricas/terapia , Cateterismo Cardíaco/efectos adversos , Cateterismo Cardíaco/instrumentación , Angiografía Coronaria/efectos adversos , Angiografía Coronaria/instrumentación , Procedimientos Endovasculares/efectos adversos , Procedimientos Endovasculares/instrumentación , Cardiopatías Congénitas/diagnóstico por imagen , Cardiopatías Congénitas/fisiopatología , Humanos , Intervención Coronaria Percutánea/efectos adversos , Intervención Coronaria Percutánea/instrumentación , Enfermedades Vasculares Periféricas/diagnóstico por imagen , Enfermedades Vasculares Periféricas/fisiopatologíaRESUMEN
Justin Davies and Andrew Tochterman speak to Adam Price-Evans, Commissioning Editor of Future Cardiology: Justin Davies is a Senior Research Fellow and Honorary Consultant Cardiologist at the National Heart and Lung Institute, Imperial College London (UK). His main research interests include the development and application of pioneering technologies in engineering to aid understanding of disease mechanisms, and in the diagnosis of pathological disease states. After completing his undergraduate training at Imperial College, he was awarded a prestigious British Heart Foundation research fellowship to undertake his PhD at Imperial College. Since then, he has trained in interventional cardiology with a specialist interest in physiological and structural assessment of coronary disease states. In 2008, he was appointed as a Walport Clinical Lecturer to support his research activities alongside his ongoing clinical commitments. Born in Greentown, Indiana (USA), Andrew holds a BSc in Chemical Engineering from Rose-Hulman Institute of Technology (IN, USA) and an MBA from the Wharton Business School (PA, USA). His experience includes roles in Quality Engineering, R&D, Clinical & Product Marketing, Marketing Management and Sales at Guidant Corporation/Abbott Vascular. Andrew joined Philips Image Guided Therapy (CA, USA) in 2012, helping launch the instant wave-free ratio (iFR) product in Europe and the United States before taking on greater responsibilities as the Physiology Segment Leader, and later assuming his current role as Coronary Segment Leader at Philips Image Guided Therapy (CA, USA).